Promising results for advanced thymic tumors

1 Views

07/02/23

Nicolas Girard, MD, PhD, Institut Curie, Paris, France, talks on promising results in systemic therapies for patients with advanced or metastatic thymic tumors. The current first-line standard of care (SOC) is chemotherapy, with response rates in patients with thymomas or thymic carcinomas of 30-40%. Following disease progression, therapies including antiangiogenics and immunotherapy have demonstrated clinical benefit for this patients population in recent clinical trials, including a progression-free survival (PFS) rate of approximately 40%. This interview took place during the virtual European Lung Cancer Congress 2022.